Flaws in ivermectin data suggest COVID-19 meta-analyses need rethinking

Data from individual patients in clinical trials should be made available by researchers, and then requested and reviewed, for meta-analyses of potential therapeutics for COVID-19, argue Kyle Sheldrick and colleagues in a Correspondence published in Nature Medicine. Using the example of research into the use of ivermectin to highlight the risks inherent in current approaches, the authors contend that immediate remediation is needed in order to prevent potential harm to patients.

This post was originally published on this site

Lawyers Lookup - LawyersLookup.ca